MPC-4326 Clinical Trials

Therapeutic Area: HIV Infection

Phase 2 Clinical Trial

MPC-4326 is a potent small-molecule orally bioavailable first-in-class inhibitor of  HIV viral maturation.  MPI plans to initiate a Phase 2b study of MPC-4326 by the end of 2009.